skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Human myometrial adrenergic receptors: identification of the beta-adrenergic receptor by (/sup 3/H)dihydroalprenolol binding

Journal Article · · Am. J. Obstet. Gynecol.; (United States)
OSTI ID:5707847

The radioactive beta-adrenergic antagonist (/sup 3/H) dihydroalprenolol (DHA) binds to particulate preparations of human myometrium in a manner compatible with binding to the beta-adrenergic receptor. The binding of DHA is rapid (attaining equilibrium in 12 minutes), readily reversible (half time = 16 minutes), high affinity (K/sub D/ = 0.50 nM), low capacity (Bmax = 70 fmoles/mg of protein), and stereoselective ((-)-propranolol is 100 times as potent as (+) -propranolol in inhibiting DHA binding). Adrenergic agonists competed for DHA binding sites in a manner compatible with beta-adrenergic interactions and mirrored ..beta../sub 2/ pharmacologic potencies: isoproterenol > epinephrine >> norepinephrine. Studies in which zinterol, a ..beta../sub 2/-adrenergic agonist, competed for DHA binding sites in human myometrial particulate indicated that at least 87% of the beta-adrenergic receptors present are ..beta../sub 2/-adrenergic receptors. Binding of DHA to human myometrial beta-adrenergic receptors provides a tool which may be used in the examination of gonadal hormonal modification of adrenergic response in human uterus as well as in the analysis of beta-adrenergic agents as potentially useful tocolytic agents.

Research Organization:
Univ. of California, San Francisco
OSTI ID:
5707847
Journal Information:
Am. J. Obstet. Gynecol.; (United States), Vol. 142:4
Country of Publication:
United States
Language:
English